The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

Antonino Capizzi, Michela Silvestri, Andrea Orsi, Renato Cutrera, Giovanni A Rossi, Oliviero Sacco

Research output: Contribution to journalArticle

Abstract

Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the = 29 wGA subpopulation when specific risk factors are present.
Original languageEnglish
JournalItalian Journal of Pediatrics
Volume43
Issue number1
DOIs
Publication statusPublished - Aug 14 2017

Keywords

  • Letter

Fingerprint Dive into the research topics of 'The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence'. Together they form a unique fingerprint.

  • Cite this